Cagent Vascular
Overview
Cagent Vascular is a medical device company focusing on innovative cardiovascular treatments, particularly through the development of serration technology used in angioplasty. The company was founded in 2014 and is headquartered in Wayne, Pennsylvania. It was co-founded by Carol A. Burns, Robert Giasolli, and Peter Schneider MD. Cagent Vascular has attracted significant investment, raising $58.2 million across several funding rounds, including a recent $30 million Series C in 2024. The company's primary product, the Serranator PTA Serration Balloon Catheter, is designed to improve outcomes for patients with peripheral arterial disease (PAD).
Recent Developments
- Series C Funding: In early 2024, Cagent Vascular successfully closed a Series C financing round exceeding $30 million, led by U.S. Venture Partners, with additional investments from Blue Ridge Medical and existing investors like Sectoral Asset Management. This funding aims to accelerate U.S. market adoption of the Serranator device and expand its product portfolio.
- Leadership Changes: Brian Walsh, former Chairman of Cagent Vascular, transitioned to the role of CEO, bringing in experience from previous leadership roles in high-growth medical device companies such as IanTECH Medical and Transcend Medical.
- Clinical Innovations: The Serranator device has shown promising results in clinical studies against traditional plain old balloon angioplasty (POBA), notably in the RECOIL study, which demonstrated significantly lower vessel recoil in below-the-knee angioplasties, highlighting its potential for superior clinical outcomes.
- Regulatory Approvals: The Serranator has received FDA 510k clearance and CE Mark approval, facilitating its use across the U.S. and parts of Europe for treating infrapopliteal and other arterial lesions.
- Market Expansion: With more than 10,000 Serranator devices used globally, Cagent Vascular is poised to further expand its market reach, leveraging its innovative technology to provide enhanced treatment options for PAD patients.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2014 |
| Headquarters | Wayne, PA, USA |
| Founders | Carol A. Burns, Robert Giasolli, Peter Schneider MD |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | U.S. Venture Partners, Blue Ridge Medical, Sectoral Asset Management |
| Industry | Surgical Devices |
| Number of Employees | 46 |
Early History
Cagent Vascular was founded in 2014 with the mission to improve the treatment of cardiovascular diseases through innovative angioplasty technology. Early efforts focused on developing the Serranator PTA Serration Balloon Catheter, which combines serration technology with angioplasty for enhanced arterial dilation. The initial years saw the securing of key funding, leading to product development milestones, and engaging with regulatory bodies to secure necessary approvals, setting a strong foundation for future growth.
Company Profile and Achievements
Cagent Vascular operates in the realm of surgical devices, specifically targeting peripheral artery disease through its proprietary serration technology. The company has established itself as a pioneer in serration balloon technology. Key milestones include:
- Product Development: Launch of the Serranator PTA Serration Balloon Catheter, aiming to provide enhanced luminal gain with minimal dissection risks.
- Regulatory Milestones: Achieving FDA clearance and CE marking, which facilitated market entry and expansion.
- Clinical Success: Success in multiple clinical studies, including the RECOIL study, demonstrating superior outcomes compared to competing technologies.
- Funding Achievements: Raising $58.2 million in venture capital funding to support continued innovation and market expansion.
Current Operations and Market Position
Cagent Vascular is actively engaged in the commercialization of its Serranator technology across the United States and Europe. Its market approach includes strategic partnerships and potentially exploring further global markets. Despite being a private company, it competes with well-established players in the surgical devices industry by emphasizing its technological edge in angioplasty. The company's strong clinical data and financial backing position it as an influential player in addressing vascular health issues, particularly PAD.
Conclusion
Cagent Vascular stands out in the surgical devices industry with its groundbreaking serration angioplasty technology, which promises improved outcomes for PAD patients. As of 2024, with robust financial backing and strategic leadership, the company is set for continued expansion and innovation. Its commitment to improving cardiovascular treatment has positioned it as a potential leader in surgical innovation, likely impacting how vascular diseases are treated globally in the coming years.